calcimimetic peptide
Etelcalcetide dose
Answer
FDA label for PARSABIV: The recommended starting dose is 5 mg administered by intravenous bolus injection three times per week at the end of hemodialysis treatment. Half-life on the label: 3 to 4 days. Trials with posted results tested 1 dose, most often 10 mg.
Not dosing advice.
FDA LABEL
What the approved labels state
PARSABIV NDA208325 · label of 2026-03-08 Regulator
The recommended starting dose is 5 mg administered by intravenous bolus injection three times per week at the end of hemodialysis treatment.
Maximum dose of 15 mg three times per week.
Half-life: 3 to 4 days (section 12.3).
IN TRIALS
Doses tested in 16 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 10 mg | 1 | 21 | 2 |
Trial register Read from the titles of arms that received Etelcalcetide (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.